Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEMarc Humbert, K. Surrey, Richard Beasley et al.|Allergy|2004Cited by 1.1k
Chronic rhinosinusitis in Europe - an underestimated disease. A GA2LEN studyDeniz Hastan, Peter Burney, W. J. Fokkens et al.|Allergy|2011Cited by 1.1k
Rhinitis and onset of asthma: a longitudinal population-based studyRafea Shaaban, Bénédicte Leynaert, Mahmoud Zureik et al.|The Lancet|2008Cited by 613
Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthmaStephen T. Holgate, А. Г. Чучалин, Jean‐Louis Hébert et al.|Clinical & Experimental Allergy|2004Cited by 520
Asthma in adults and its association with chronic rhinosinusitis: The GA <sup>2</sup> LEN survey in EuropeDeborah Jarvis, Peter Burney, R B Newson et al.|Allergy|2011Cited by 485